- Interim results from ongoing ORION-3 study demonstrated sustained lowering of LDL-C by more than 50 percent, with time-averaged absolute reductions of 59.4 mg/dL
- No material safety issues observed in the study
- Pivotal Phase 3 readouts for inclisiran expected in 3Q-2019 followed by regulatory filings expected in the U.S. in 4Q-2019 and Europe in 1Q-2020
Catalyst
Slingshot members are tracking this event:
Data from The Medicines Company's(MDCO) Phase 2 ORION 3 study of Inclisiran in Cardiovascular disease (ASCVD) Released
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MDCO |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 18, 2019
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Inclisiran, Orion Phase 2a Study, Cardiovascular Disease, Cholesterol Lowering
